Matriptase-2 的胞外域在小鼠体内以非蛋白水解方式发挥抑制 hepcidin 表达的重要作用
研究利用 Mt2 突变体与 Tmprss6-/- 小鼠解析 Mt2 非蛋白水解与蛋白水解活性的贡献。蛋白酶失活全长 Mt2(Mt2S762A)及缺失催化域截短体(Mt2mask)研究提示,抑制 hepcidin 表达需要催化域但不需要其蛋白水解活性,该过程可能通过 Mt2 胞外域与 Hjv、Hfe 结合完成。铁难治性缺铁性贫血相关突变体 Mt2I286F 可被激活但抑制 hepcidin 能力大幅受损,且与 Hjv、ActRIIA、Hfe 相互作用减少。
要点
- Mt2 抑制 hepcidin 表达需要催化域,但不需要其蛋白水解活性。
- Mt2 胞外域与 Hjv、Hfe 结合可能介导对 hepcidin 的抑制。
- Mt2I286F 可被激活,但抑制 hepcidin 能力大幅受损,与 Hjv、ActRIIA、Hfe 相互作用减少。
核心结论
- 支持底物与 Mt2 的相互作用起决定性作用的观点,并提示蛋白水解活性不是调控 MT2 功能用于临床应用的合适靶点。
研究设计与样本
- 利用 Mt2 突变体与 Tmprss6-/- 小鼠解析 Mt2 非蛋白水解与蛋白水解活性的贡献。
主要发现
- 蛋白酶失活全长 Mt2(Mt2S762A)及缺失催化域截短体(Mt2mask)研究提示,抑制 hepcidin 表达需要催化域但不需要其蛋白水解活性。
- 该过程可能通过 Mt2 胞外域与 Hjv、Hfe 结合完成。
- Mt2 在肝癌细胞过表达时特异性切割 hepcidin 诱导通路关键组分,包括 Hjv、Alk3、ActRIIA 和 Hfe。
- 铁难治性缺铁性贫血相关突变体 Mt2I286F 可被激活,但抑制 hepcidin 表达的能力大幅受损。
- 免疫共沉淀分析显示 Mt2I286F 而非 Mt2S762A 与 Hjv、ActRIIA 和 Hfe 的相互作用减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Matriptase-2 (MT2), encoded by TMPRSS6, is a membrane-anchored serine protease that plays a key role in suppressing hepatic hepcidin expression. MT2 is synthesized as a zymogen and undergoes autocleavage for activation. Previous studies suggest that MT2 suppresses hepcidin by cleaving hemojuvelin and other components of the bone morphogenetic protein-signaling pathway. However, the underlying mechanism is still debatable. Here we dissected the contributions of the nonproteolytic and proteolytic activities of Mt2 by taking advantage of Mt2 mutants and Tmprss6-/- mice. Studies of the protease-dead full-length Mt2 (Mt2S762A) and the truncated Mt2 that lacks the catalytic domain (Mt2mask) indicate that the catalytic domain, but not its proteolytic activity, was required for Mt2 to suppress hepcidin expression. This process was likely accomplished by the binding of Mt2 ectodomain to Hjv and Hfe. We found that Mt2 specifically cleaved the key components of the hepcidin-induction pathway, including Hjv, Alk3, ActRIIA, and Hfe, when overexpressed in hepatoma cells. Nevertheless, studies of a murine iron-refractory iron-deficiency anemia-causing mutant (Mt2I286F) in the complement protein subcomponents C1r/C1s, urchin embryonic growth factor, and bone morphogenetic protein 1 domain indicate that Mt2I286F can be activated, but it exhibited a largely compromised ability to suppress hepcidin expression. Coimmunoprecipitation analysis revealed that Mt2I286F, but not Mt2S762A, had reduced interactions with Hjv, ActRIIA, and Hfe. In addition, increased expression of a serine protease inhibitor, the hepatocyte growth factor activator inhibitor-2, in the liver failed to alter hepcidin. Together, these observations support the idea that the substrate interaction with Mt2 plays a determinant role and suggest that the proteolytic activity is not an appropriate target to modulate the function of MT2 for clinical applications.
引用
- Enns CA, Jue S, Zhang AS, et al. The ectodomain of matriptase-2 plays an important nonproteolytic role in suppressing hepcidin expression in mice. Blood. 2020. PMID: 32384154. doi:10.1182/blood.2020005222
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。